Pay in 4 interest-free payments of $7.02 Learn more
Ships within 48 hours · Estimated delivery Sep 29 - Oct 4
REDEFINE 1 (Garvey et al., NEJM 2025) is the only Phase 3 trial of an amylin + incretin co-administered combination, pairing cagrilintide 2.4 mg with semaglutide 2.4 mg
Beyond the GLP-1 receptor, it also targets the GIP (glucose-dependent insulinotropic polypeptide) receptor
Cardiac Workload Reduction (Metoprolol Succinate ER) Metoprolol Succinate ER is a long-acting beta-blocker that slows heart rate, reduces cardiac output, and decreases the workload on the heart
We continue to refine programs so patients get the best results possible
US$ 25.27
US$ 22.11
US$ 22.55
US$ 25.41
US$ 26.60
